BOSTON (Reuters) – Impax Laboratories Inc went to trial on Monday over claims by major retailers and consumers that the company agreed to delay launching a generic version of Solodyn in exchange for millions of dollars from the acne medication’s manufacturer.
Source: Reuters Medical News